CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Accuray Q1 revenue falls on product sales, orders decline

By Reuters News


Overview

  • Radiation therapy systems maker's fiscal Q1 revenue fell 8% yr/yr as product revenue dropped 26%

  • Service revenue grew 4% yr/yr, supported by pricing actions and installed base growth

  • Company posted GAAP net income due to a non-cash debt-extinguishment gain, while adjusted EBITDA turned positive


Outlook

  • Company continues not to provide formal fiscal 2027 revenue or adjusted EBITDA guidance

  • Company says focus for fiscal 2027 is on execution and improving product revenue and orders


Result Drivers

  • SERVICE REVENUE GROWTH - Co said service revenue rose 4% yr/yr, driven by service contract pricing actions and nearly 3% growth in global installed base

  • PRODUCT REVENUE DECLINE - Product revenue fell 26% yr/yr to $27.3 mln

  • COST REDUCTIONS - Co said transformation initiatives, including headcount reductions and more efficient use of partners, lowered operating expenses by 29% yr/yr (excluding goodwill impairment)


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Revenue

$86.52 mln

Q1 EPS

$0.07

Q1 Net Income

$10.13 mln

Q1 Gross Profit

$26.08 mln

Q1 Operating Loss

$36.50 mln

Q1 Operating Expenses

$62.59 mln


Reuters Recommended Reads

  • Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices

  • Nov 2 - SI-BONE Q3 revenue rises 14.5%, slightly beats estimates

  • Nov 3 - RxSight Q3 revenue falls on competitive pressures


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.